Biomarkers in Alzheimer's disease drug development.
Biomarkers may be of great value in Alzheimer's disease drug development to select the most optimal drug candidates for large and expensive phase 3 clinical trials. Biomarkers will also be important to provide evidence that a drug affects the underlying pathophysiology of the disease, which, together with a beneficial effect on the clinical course, will be essential for labeling the drug as having a disease-modifying effect.
Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden. kaj.blennow@neuro.gu.se
Kaj
K
Blennow
D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy*; D015415:Biomarkers / Q000378:metabolism*; D002986:Clinical Trials as Topic; D055808:Drug Discovery; D018740:Genetic Heterogeneity; D006801:Humans
D015415:Biomarkers